Clinical studies of moxalactam in complicated urinary tract infections

Moxalactam in a daily dose of 0.5-2 g was administered for five days to 276 patients with complicated urinary tract infections. A satisfactory clinical response was obtained in 71% of the patients. All patients responded well except for those with infections caused by Streptococcus faecalis and Pseudomonas species, including Pseudomonas aeruginosa. Adverse reactions were observed in six patients (2.2%), but no adverse reaction required discontinuation of treatment. Abnormal results in clinical laboratory tests were found in four patients. Thus, it appears that moxalactam is a reliable and useful antibiotic for the treatment of complicated urinary tract infections.